Skip to main content
Top
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Hepatitis B | Research

Prediction of hepatocellular carcinoma risk in patients with chronic liver disease from dynamic modular networks

Authors: Yinying Chen, Wei Yang, Qilong Chen, Qiong Liu, Jun Liu, Yingying Zhang, Bing Li, Dongfeng Li, Jingyi Nan, Xiaodong Li, Huikun Wu, Xinghua Xiang, Yehui Peng, Jie Wang, Shibing Su, Zhong Wang

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Background

Discovering potential predictive risks in the super precarcinomatous phase of hepatocellular carcinoma (HCC) without any clinical manifestations is impossible under normal paradigm but critical to control this complex disease.

Methods

In this study, we utilized a proposed sequential allosteric modules (AMs)-based approach and quantitatively calculated the topological structural variations of these AMs.

Results

We found the total of 13 oncogenic allosteric modules (OAMs) among chronic hepatitis B (CHB), cirrhosis and HCC network used SimiNEF. We obtained the 11 highly correlated gene pairs involving 15 genes (r > 0.8, P < 0.001) from the 12 OAMs (the out-of-bag (OOB) classification error rate < 0.5) partial consistent with those in independent clinical microarray data, then a three-gene set (cyp1a2-cyp2c19-il6) was optimized to distinguish HCC from non-tumor liver tissues using random forests with an average area under the curve (AUC) of 0.973. Furthermore, we found significant inhibitory effect on the tumor growth of Bel-7402, Hep 3B and Huh7 cell lines in zebrafish treated with the compounds affected those three genes.

Conclusions

These findings indicated that the sequential AMs-based approach could detect HCC risk in the patients with chronic liver disease and might be applied to any time-dependent risk of cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA. 2010;107:264–9.PubMedCrossRef Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA. 2010;107:264–9.PubMedCrossRef
3.
go back to reference Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet. 2012;44:1117–21.PubMedCrossRef Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet. 2012;44:1117–21.PubMedCrossRef
4.
go back to reference Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology. 2009;50:472–80.PubMedCrossRef Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology. 2009;50:472–80.PubMedCrossRef
5.
go back to reference Jiang YF, He B, Li NP, Ma J, Gong GZ, Zhang M. The oncogenic role of NS5A of hepatitis C virus is mediated by up-regulation of survivin gene expression in the hepatocellular cell through p53 and NF-κB pathways. Cell Biol Int. 2011;35:1225–32.PubMedCrossRef Jiang YF, He B, Li NP, Ma J, Gong GZ, Zhang M. The oncogenic role of NS5A of hepatitis C virus is mediated by up-regulation of survivin gene expression in the hepatocellular cell through p53 and NF-κB pathways. Cell Biol Int. 2011;35:1225–32.PubMedCrossRef
6.
go back to reference Diao J, Pantua H, Ngu H, Komuves L, Diehl L, Schaefer G, et al. Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J Virol. 2012;86:10935–49.PubMedPubMedCentralCrossRef Diao J, Pantua H, Ngu H, Komuves L, Diehl L, Schaefer G, et al. Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J Virol. 2012;86:10935–49.PubMedPubMedCentralCrossRef
7.
go back to reference Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10573–83.PubMedPubMedCentralCrossRef Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10573–83.PubMedPubMedCentralCrossRef
8.
go back to reference Li L, Chen J, Chen X, Tang J, Guo H, Wang X, et al. Serum miRNAs as predictive and preventive riskfor pre-clinical hepatocellular carcinoma. Cancer Lett. 2016;373:234–40.PubMedPubMedCentralCrossRef Li L, Chen J, Chen X, Tang J, Guo H, Wang X, et al. Serum miRNAs as predictive and preventive riskfor pre-clinical hepatocellular carcinoma. Cancer Lett. 2016;373:234–40.PubMedPubMedCentralCrossRef
9.
go back to reference He Y, Dang Q, Li J, Zhang Q, Yu X, Xue M, et al. Prediction of hepatocellular carcinoma prognosis based on expression of an immune-related gene set. Aging. 2020;12:965–77.PubMedPubMedCentralCrossRef He Y, Dang Q, Li J, Zhang Q, Yu X, Xue M, et al. Prediction of hepatocellular carcinoma prognosis based on expression of an immune-related gene set. Aging. 2020;12:965–77.PubMedPubMedCentralCrossRef
11.
go back to reference Chen L, Liu R, Liu ZP, Li M, Aihara K. Detecting early-warning signals for sudden deterioration of complex diseases by dynamical network biomarkers. Sci Rep. 2012;2:342.PubMedPubMedCentralCrossRef Chen L, Liu R, Liu ZP, Li M, Aihara K. Detecting early-warning signals for sudden deterioration of complex diseases by dynamical network biomarkers. Sci Rep. 2012;2:342.PubMedPubMedCentralCrossRef
12.
go back to reference Wang Z, Liu J, Yu Y, Chen Y, Wang Y. Modular pharmacology: the next paradigm in drug discovery. Expert Opin Drug Discov. 2012;7:667–77.PubMedCrossRef Wang Z, Liu J, Yu Y, Chen Y, Wang Y. Modular pharmacology: the next paradigm in drug discovery. Expert Opin Drug Discov. 2012;7:667–77.PubMedCrossRef
14.
go back to reference Chen YY, Yu YN, Zhang YY, Li B, Liu J, Li DF, et al. Quantitative determination of flexible pharmacological mechanisms based on topological variation in mice anti-ischemic modular networks. PLoS ONE. 2016;11:e0158379.PubMedPubMedCentralCrossRef Chen YY, Yu YN, Zhang YY, Li B, Liu J, Li DF, et al. Quantitative determination of flexible pharmacological mechanisms based on topological variation in mice anti-ischemic modular networks. PLoS ONE. 2016;11:e0158379.PubMedPubMedCentralCrossRef
17.
18.
19.
go back to reference Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S, et al. KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res. 2011;39:W316-22.PubMedPubMedCentralCrossRef Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S, et al. KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res. 2011;39:W316-22.PubMedPubMedCentralCrossRef
20.
go back to reference Association CM. Chronic hepatitis B prevention and treatment guidelines. Chinese J Infect Dis. 2001;19:56–62. Association CM. Chronic hepatitis B prevention and treatment guidelines. Chinese J Infect Dis. 2001;19:56–62.
21.
go back to reference Zhang YX, Wei BH. Standard of clinic diagnosis, syndrome differentiation and assessing curative effect on hepatocirrhosis. Chin J Integrated Trad West Med Gastro-spleen. 1994;14:237–8. Zhang YX, Wei BH. Standard of clinic diagnosis, syndrome differentiation and assessing curative effect on hepatocirrhosis. Chin J Integrated Trad West Med Gastro-spleen. 1994;14:237–8.
22.
go back to reference Yang BH. Chinese Society of Liver Cancer: clinical diagnosis and staging criteria for primary hepatocellular carcinoma. Zhongguo Ganzangbing Zazhi. 2001;9:324–30. Yang BH. Chinese Society of Liver Cancer: clinical diagnosis and staging criteria for primary hepatocellular carcinoma. Zhongguo Ganzangbing Zazhi. 2001;9:324–30.
23.
go back to reference Lu YY, Chen QL, Guan Y, Guo ZZ, Zhang H, Zhang W, et al. Transcriptional profiling and co-expression network analysis identifies potential biomarkers to differentiate chronic hepatitis B and the caused cirrhosis. Mol Biosyst. 2014;10:1117–25.PubMedCrossRef Lu YY, Chen QL, Guan Y, Guo ZZ, Zhang H, Zhang W, et al. Transcriptional profiling and co-expression network analysis identifies potential biomarkers to differentiate chronic hepatitis B and the caused cirrhosis. Mol Biosyst. 2014;10:1117–25.PubMedCrossRef
24.
go back to reference Lu YY, Chen QL, Guan Y, Guo ZZ, Zhang H, Zhang W, et al. Study of ZHENG differentiation in hepatitis B-caused cirrhosis: a transcriptional profiling analysis. BMC Complement Altern Med. 2014;14:371.PubMedPubMedCentralCrossRef Lu YY, Chen QL, Guan Y, Guo ZZ, Zhang H, Zhang W, et al. Study of ZHENG differentiation in hepatitis B-caused cirrhosis: a transcriptional profiling analysis. BMC Complement Altern Med. 2014;14:371.PubMedPubMedCentralCrossRef
25.
go back to reference Guo Z, Yu S, Guan Y, Li YY, Lu YY, Zhang H, et al. Molecular mechanisms of same TCM syndrome for different diseases and different TCM syndrome for same disease in chronic hepatitis B and liver cirrhosis. Evid Based Complement Alternat Med. 2012;2012:120350.PubMedPubMedCentralCrossRef Guo Z, Yu S, Guan Y, Li YY, Lu YY, Zhang H, et al. Molecular mechanisms of same TCM syndrome for different diseases and different TCM syndrome for same disease in chronic hepatitis B and liver cirrhosis. Evid Based Complement Alternat Med. 2012;2012:120350.PubMedPubMedCentralCrossRef
26.
go back to reference Gertler R, Rosenberg R, Fuehrer K, Dahm M, Nekarda H, Siewert JR. Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. In: Allgayer H, Heiss MM, Schildberg FW, editors. Molecular staging of cancer. Recent results in cancer research. Berlin: Springer; 2003. p. 149–55.CrossRef Gertler R, Rosenberg R, Fuehrer K, Dahm M, Nekarda H, Siewert JR. Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. In: Allgayer H, Heiss MM, Schildberg FW, editors. Molecular staging of cancer. Recent results in cancer research. Berlin: Springer; 2003. p. 149–55.CrossRef
27.
go back to reference Houtao D. Interpreting tree ensembles with inTrees. Int J Data Sci Anal. 2019;7:277–87.CrossRef Houtao D. Interpreting tree ensembles with inTrees. Int J Data Sci Anal. 2019;7:277–87.CrossRef
28.
go back to reference Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B 2019 version) (Article in Chinese). Zhonghua Gan Zang Bing Za Zhi. 2019;27:938–61. Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B 2019 version) (Article in Chinese). Zhonghua Gan Zang Bing Za Zhi. 2019;27:938–61.
29.
go back to reference Zhou F, Shang W, Yu X, Tian J. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018;38:741–67.PubMedCrossRef Zhou F, Shang W, Yu X, Tian J. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018;38:741–67.PubMedCrossRef
30.
go back to reference Bhattacharya S, Steele R, Shrivastava S, Chakraborty S, Di Bisceglie AM, Ray RB. Serum miR-30e and miR-223 as novel noninvasive biomarkers for hepatocellular carcinoma. Am J Pathol. 2016;186:242–7.PubMedPubMedCentralCrossRef Bhattacharya S, Steele R, Shrivastava S, Chakraborty S, Di Bisceglie AM, Ray RB. Serum miR-30e and miR-223 as novel noninvasive biomarkers for hepatocellular carcinoma. Am J Pathol. 2016;186:242–7.PubMedPubMedCentralCrossRef
31.
go back to reference Brodeur CM, Thibault P, Durand M, Perreault JP, Bisaillon M. Dissecting the expression landscape of cytochromes P450 in hepatocellular carcinoma: towards novel molecular biomarkers. Genes Cancer. 2019;10:97–108.PubMedPubMedCentralCrossRef Brodeur CM, Thibault P, Durand M, Perreault JP, Bisaillon M. Dissecting the expression landscape of cytochromes P450 in hepatocellular carcinoma: towards novel molecular biomarkers. Genes Cancer. 2019;10:97–108.PubMedPubMedCentralCrossRef
32.
go back to reference European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.CrossRef European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.CrossRef
33.
go back to reference Li B, Liu J, Zhang YY, Wang PQ, Yu YN, Kang RX, et al. Quantitative identification of compound-dependent on-modules and differential allosteric modules from homologous ischemic networks. CPT Pharmacometrics Syst Pharmacol. 2016;5:575–84.PubMedPubMedCentralCrossRef Li B, Liu J, Zhang YY, Wang PQ, Yu YN, Kang RX, et al. Quantitative identification of compound-dependent on-modules and differential allosteric modules from homologous ischemic networks. CPT Pharmacometrics Syst Pharmacol. 2016;5:575–84.PubMedPubMedCentralCrossRef
34.
go back to reference Yu Y, Zhang X, Li B, Zhang Y, Liu J, Li H, et al. Entropy-based divergent and convergent modular pattern reveals additive and synergistic anticerebral ischemia mechanisms. Exp Biol Med. 2016;241:2063–74.CrossRef Yu Y, Zhang X, Li B, Zhang Y, Liu J, Li H, et al. Entropy-based divergent and convergent modular pattern reveals additive and synergistic anticerebral ischemia mechanisms. Exp Biol Med. 2016;241:2063–74.CrossRef
35.
go back to reference Tokusashi Y, Asai K, Tamakawa S, Yamamoto M, Yoshie M, Yaginuma Y, et al. Expression of NGF in hepatocellular carcinoma cells with its receptors in non-tumor cell components. Int J Cancer. 2005;114:39–45.PubMedCrossRef Tokusashi Y, Asai K, Tamakawa S, Yamamoto M, Yoshie M, Yaginuma Y, et al. Expression of NGF in hepatocellular carcinoma cells with its receptors in non-tumor cell components. Int J Cancer. 2005;114:39–45.PubMedCrossRef
36.
go back to reference Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infectionPathogenèse de l’infection par le virus de l’hépatite B. Pathol Biol. 2010;58:258–66.PubMedCrossRef Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infectionPathogenèse de l’infection par le virus de l’hépatite B. Pathol Biol. 2010;58:258–66.PubMedCrossRef
37.
go back to reference Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123–35.PubMedCrossRef Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123–35.PubMedCrossRef
38.
go back to reference Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010;29:4989–5005.PubMedCrossRef Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010;29:4989–5005.PubMedCrossRef
39.
go back to reference Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, et al. TGF-b-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012;22:291–303.PubMedPubMedCentralCrossRef Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, et al. TGF-b-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012;22:291–303.PubMedPubMedCentralCrossRef
40.
go back to reference Zhang Y, Qiu Z, Wei L, Tang R, Lian B, Zhao Y, et al. Integrated analysis of mutation data from various sources identifies key genes and signaling pathways in hepatocellular carcinoma. PLoS ONE. 2014;9:e100854.PubMedPubMedCentralCrossRef Zhang Y, Qiu Z, Wei L, Tang R, Lian B, Zhao Y, et al. Integrated analysis of mutation data from various sources identifies key genes and signaling pathways in hepatocellular carcinoma. PLoS ONE. 2014;9:e100854.PubMedPubMedCentralCrossRef
41.
go back to reference Bouchard MJ, Wang L, Schneider RJ. Activation of focal adhesion kinase by hepatitis B virus HBx protein: multiple functions in viral replication. J Virol. 2006;80:4406–14.PubMedPubMedCentralCrossRef Bouchard MJ, Wang L, Schneider RJ. Activation of focal adhesion kinase by hepatitis B virus HBx protein: multiple functions in viral replication. J Virol. 2006;80:4406–14.PubMedPubMedCentralCrossRef
42.
go back to reference Lara-Pezzi E, Roche S, Andrisani OM, Sánchez-Madrid F, López-Cabrera M. The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner. Oncogene. 2001;20:3323–31.PubMedCrossRef Lara-Pezzi E, Roche S, Andrisani OM, Sánchez-Madrid F, López-Cabrera M. The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner. Oncogene. 2001;20:3323–31.PubMedCrossRef
43.
go back to reference Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001;84:1377–83.PubMedPubMedCentralCrossRef Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001;84:1377–83.PubMedPubMedCentralCrossRef
44.
go back to reference Liu J, Ahiekpor A, Li L, Li X, Arbuthnot P, Kew M, et al. Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer. Int J Cancer. 2009;125:1894–901.PubMedPubMedCentralCrossRef Liu J, Ahiekpor A, Li L, Li X, Arbuthnot P, Kew M, et al. Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer. Int J Cancer. 2009;125:1894–901.PubMedPubMedCentralCrossRef
45.
46.
go back to reference Huang CF, Lin SS, Ho YC, Chen FL, Yang CC. The immune response induced by hepatitis B virus principal antigens. Cell Mol Immunol. 2006;3:97–106.PubMed Huang CF, Lin SS, Ho YC, Chen FL, Yang CC. The immune response induced by hepatitis B virus principal antigens. Cell Mol Immunol. 2006;3:97–106.PubMed
47.
go back to reference Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol. 2009;86:513–28.PubMedPubMedCentralCrossRef Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol. 2009;86:513–28.PubMedPubMedCentralCrossRef
48.
go back to reference Beyoğlu D, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, Dufour JF, et al. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology. 2013;58:229–38.PubMedCrossRef Beyoğlu D, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, Dufour JF, et al. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology. 2013;58:229–38.PubMedCrossRef
49.
go back to reference Yuan JM, Gao YT, Ong CN, Ross RK, Yu MC. Prediagnostic level of serum retinol in relation to reduced risk of hepatocellular carcinoma. J Natl Cancer Inst. 2006;98:482–90.PubMedCrossRef Yuan JM, Gao YT, Ong CN, Ross RK, Yu MC. Prediagnostic level of serum retinol in relation to reduced risk of hepatocellular carcinoma. J Natl Cancer Inst. 2006;98:482–90.PubMedCrossRef
50.
go back to reference Liu H, Lou G, Li C, Wang X, Cederbaum AI, Gan L, et al. HBx inhibits CYP2E1 gene expression via downregulating HNF4α in human hepatoma cells. PLoS ONE. 2014;9:e107913.PubMedPubMedCentralCrossRef Liu H, Lou G, Li C, Wang X, Cederbaum AI, Gan L, et al. HBx inhibits CYP2E1 gene expression via downregulating HNF4α in human hepatoma cells. PLoS ONE. 2014;9:e107913.PubMedPubMedCentralCrossRef
51.
go back to reference Kuhn M, Johnson K. Applied Predictive Modeling. 1st ed. New York: Springer-Verlag; 2013.CrossRef Kuhn M, Johnson K. Applied Predictive Modeling. 1st ed. New York: Springer-Verlag; 2013.CrossRef
52.
go back to reference Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied logistic regression. 3rd ed. New Jersey: Wiley; 2013.CrossRef Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied logistic regression. 3rd ed. New Jersey: Wiley; 2013.CrossRef
53.
go back to reference Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 2009;124:2766–70.PubMedCrossRef Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 2009;124:2766–70.PubMedCrossRef
54.
go back to reference Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, Boncimino A, et al. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol. 2008;19:353–8.PubMedCrossRef Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, Boncimino A, et al. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol. 2008;19:353–8.PubMedCrossRef
Metadata
Title
Prediction of hepatocellular carcinoma risk in patients with chronic liver disease from dynamic modular networks
Authors
Yinying Chen
Wei Yang
Qilong Chen
Qiong Liu
Jun Liu
Yingying Zhang
Bing Li
Dongfeng Li
Jingyi Nan
Xiaodong Li
Huikun Wu
Xinghua Xiang
Yehui Peng
Jie Wang
Shibing Su
Zhong Wang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-02791-9

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.